Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2020

View Archived Issues

First patient enrolled in phase I study of GEM-103

FDA clears IND for ACE-1702 for the treatment of HER2-expressing solid tumors

Moderna begins phase II study of CMV vaccine mRNA-1647

Nomacopan achieves primary endpoint at interim analysis of phase III CAPSTONE study

Positive results from pivotal phase II study of loncastuximab tesirine in DLBCL

Novel ATX inhibitor shows promise as IOP-lowering therapy in vivo

Daiichi Sankyo presents a new orally potent analgesic, DS-54360155

Mutations in TTC29 gene linked to male infertility

Heptares Therapeutics describes new muscarinic acetylcholine M1 and/or M4 receptor agonists

New tankyrase 1/2 inhibitors patented by Forschungsverbund Berlin and collaborators

Curadev Pharma synthesizes new STING agonists

FGF21 switches sides in pancreatitis

Amyloid after amnesia?

Merck & Co. discovers PCSK9 inhibitors

Treatment effects may spread in LCA gene therapy

New NRTK1 inhibitors disclosed by Beijing Innocare Pharmaceutical Technology

Xuanzhu (Hainan) Biopharmaceutical identifies farnesoid X receptor agonists

Bio-Thera launches adalimumab biosimilar Qletli in China

AKCEA-TTR-LRx begins phase III cardiovascular outcomes study

ContraFect begins dosing in phase III study of exebacase for S. aureus bacteremia

Seelos reports interim phase I data on intranasal racemic ketamine

New REPAIR-MS phase II study begins with CNM-Au8 for MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...